Sickle-Cell Anemia Therapeutics

Sickle-Cell Anemia Therapeutics

Global Sickle-Cell Anemia Therapeutics Market to Reach US$4.9 Billion by 2030

The global market for Sickle-Cell Anemia Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 12.5% over the analysis period 2023-2030. Hydroxyurea Drug, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Oxbryta Drug segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$581.5 Million While China is Forecast to Grow at 20.8% CAGR

The Sickle-Cell Anemia Therapeutics market in the U.S. is estimated at US$581.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.6% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Sickle-Cell Anemia Therapeutics Market - Key Trends and Drivers Summarized

Sickle-cell anemia is a genetic blood disorder characterized by the presence of abnormal hemoglobin, known as hemoglobin S, which distorts red blood cells into a sickle shape. These misshapen cells can block blood flow, leading to pain, infections, acute chest syndrome, stroke, and other severe complications. The standard treatment has long been focused on managing symptoms and preventing complications, with options like pain relief medications, antibiotics, and blood transfusions. Hydroxyurea, a drug that induces the production of fetal hemoglobin, has been the mainstay of disease-modifying therapy, reducing the frequency of painful crises and acute chest syndrome. Bone marrow transplants offer a potential cure but are limited by donor availability and the risks associated with the procedure.

Recent advancements in sickle-cell anemia therapeutics are promising, bringing hope for more effective and curative treatments. Gene therapy has emerged as a groundbreaking approach, with several clinical trials demonstrating the potential to correct the genetic defect responsible for the disease. Techniques such as CRISPR-Cas9 gene editing and lentiviral vector-mediated gene addition are at the forefront of these innovations. Additionally, new drug therapies are being developed to target the underlying pathophysiology of sickle-cell disease. These include voxelotor, which increases hemoglobin`s affinity for oxygen, and crizanlizumab, a monoclonal antibody that prevents the adhesion of sickle cells to blood vessel walls, thereby reducing vaso-occlusive episodes. The pipeline for sickle-cell therapeutics is robust, with numerous investigational drugs in various stages of development.

The growth in the sickle-cell anemia therapeutics market is driven by several factors. Technological advancements in gene therapy and genome editing are expanding treatment possibilities and improving efficacy. The increasing prevalence of sickle-cell anemia, particularly in regions with high rates of the disease, such as sub-Saharan Africa, India, the Middle East, and certain parts of the United States, is driving demand for effective treatments. Enhanced diagnostic capabilities are facilitating early detection and intervention, which is crucial for managing the disease and improving patient outcomes. Significant investments in research and development by pharmaceutical companies are accelerating the discovery and commercialization of novel therapies. Regulatory support, including orphan drug designations and fast-track approvals, is facilitating quicker access to new treatments. Additionally, the growing adoption of precision medicine is generating demand for personalized therapies tailored to individual genetic profiles. Patient advocacy groups and public health initiatives are also playing a vital role in raising awareness, promoting early diagnosis, and supporting the adoption of innovative treatments, thereby contributing to the overall growth of the sickle-cell anemia therapeutics market.

Select Competitors (Total 86 Featured) -

• Agios Pharmaceuticals, Inc.
• Beam Therapeutics
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• Chiesi Global Rare Disease
• CRISPR Therapeutics
• CSL Ltd.
• Editas Medicine, Inc.
• Emmaus Life Sciences, Inc.
• GSK Plc
• Novartis AG
• Novo Nordisk A/S
• Pfizer, Inc.
• Vertex Pharmaceuticals Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.